T Cell Selective Apoptosis by a Novel Immunosuppressant, FTY720, is Closely Regulated with Bcl-2

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2002 Nov 14

PMID 12429567

Citations 12

Authors

Yukitoshi Nagahara

Masahiko Ikekita

Takahisa Shinomiya

Affiliations

Soon will be listed here.

Abstract

1. A novel immunosuppressant FTY720 caused a significant decrease in peripheral T lymphocytes, but not in B lymphocytes upon oral administration. This decrease was mainly a result of FTY720-induced apoptosis. In this study, we confirmed FTY720-induced T cell selective apoptosis using lymphoma cell lines in vitro. 2. Viability loss, DNA fragmentation, Annexin V binding, and caspases activation (caspase-3, -8, and -9) were observed in Jurkat cells (T lymphoma cells), but not significantly in BALL-1 cells (B lymphoma cells). These results indicated that FTY720 selectively induced apoptosis in T cell lymphoma to a greater extent than in B cell lymphoma, a finding that is similar to the result observed when FTY720 was treated with T lymphocytes and B lymphocytes in vitro. 3. FTY720 released cytochrome c from mitochondria in Jurkat intact cells as well as from isolated Jurkat mitochondria directly, but not from mitochondria in BALL-1 cells nor from isolated BALL-1 mitochondria. 4. BALL-1 cells and B cells had more abundant mitochondria-localized anti-apoptotic protein Bcl-2 than did Jurkat cells and T cells. 5. FTY720-induced apoptosis is inhibited by the overexpression of Bcl-2, suggesting that the cellular Bcl-2 level regulates the sensitivity to FTY720.

Citing Articles

S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes.

Dixit D, Hallisey V, Zhu E, Okuniewska M, Cadwell K, Chipuk J J Clin Invest. 2024; 134(4).

PMID: 38194271 PMC: 10869180. DOI: 10.1172/JCI174984.

Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer.

Wang Z, Qin Y, Wang X, Zhang T, Hu Y, Wang D Int J Nanomedicine. 2023; 18:4023-4042.

PMID: 37520302 PMC: 10378575. DOI: 10.2147/IJN.S413217.

Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma Wildtype.

Kashani E, Vassella E Cancers (Basel). 2022; 14(21).

PMID: 36358647 PMC: 9654311. DOI: 10.3390/cancers14215227.

Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.

Bail K, Notz Q, Rovituso D, Schampel A, Wunsch M, Koeniger T J Neuroinflammation. 2017; 14(1):148.

PMID: 28738885 PMC: 5525315. DOI: 10.1186/s12974-017-0924-4.

The emerging role of FTY720 (Fingolimod) in cancer treatment.

White C, Alshaker H, Cooper C, Winkler M, Pchejetski D Oncotarget. 2016; 7(17):23106-27.

PMID: 27036015 PMC: 5029614. DOI: 10.18632/oncotarget.7145.

References

Ueda H, Takahara S, Azuma H, Kusaka M, Suzuki S, Katsuoka Y . Effect of a novel immunosuppressant, FTY720, on allograft survival after renal transplant in rats. Eur Surg Res. 2000; 32(5):279-83. DOI: 10.1159/000008776. View

Wang J, Takahara S, Nonomura N, Ichimaru N, Toki K, Azuma H . Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate. 1999; 40(1):50-5. DOI: 10.1002/(sici)1097-0045(19990615)40:1<50::aid-pros6>3.0.co;2-n. View

Fujino M, Li X, Guo L, Amano T, Suzuki S . Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat. Int Immunopharmacol. 2001; 1(11):2011-21. DOI: 10.1016/s1567-5769(01)00130-8. View

Van Furth R, Gassmann A . The effect of azathioprine (Imuran) on the cell cycle of promonocytes and the production of monocytes in the bone marrow. J Exp Med. 1975; 141(3):531-46. PMC: 2189704. DOI: 10.1084/jem.141.3.531. View

Koyama H, Tsuji M . Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol. 1983; 32(23):3547-53. DOI: 10.1016/0006-2952(83)90301-5. View

Nelson P . Cyclosporine. Surg Gynecol Obstet. 1984; 159(3):297-308. View

Ngan B, Chen-Levy Z, Weiss L, Warnke R, Cleary M . Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med. 1988; 318(25):1638-44. DOI: 10.1056/NEJM198806233182502. View

Dumont F, Staruch M, Koprak S, Melino M, Sigal N . Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990; 144(1):251-8. View

Zutter M, Hockenbery D, Silverman G, Korsmeyer S . Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood. 1991; 78(4):1062-8. View

10.

Kondo E, Nakamura S, Onoue H, Matsuo Y, Yoshino T, Aoki H . Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. Blood. 1992; 80(8):2044-51. View

11.

Tamaru Y, Miyawaki T, Iwai K, Tsuji T, Nibu R, Yachie A . Absence of bcl-2 expression by activated CD45RO+ T lymphocytes in acute infectious mononucleosis supporting their susceptibility to programmed cell death. Blood. 1993; 82(2):521-7. View

12.

Krajewski S, Tanaka S, Takayama S, Schibler M, Fenton W, Reed J . Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 1993; 53(19):4701-14. View

13.

Kupiec-Weglinski J, Wasowska B, Papp I, Schmidbauer G, Sayegh M, Baldwin 3rd W . CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines. J Immunol. 1993; 151(9):5053-61. View

14.

Tamura A, Li X, Funeshima N, Enosawa S, Amemiya H, Kitajima M . Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation. Surgery. 2000; 127(1):47-54. DOI: 10.1067/msy.2000.100884. View

15.

Furukawa H, Suzuki T, Jin M, Yamashita K, Taniguchi M, Magata S . Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. Transplantation. 2000; 69(2):235-41. DOI: 10.1097/00007890-200001270-00008. View

16.

Toker A . Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol Pharmacol. 2000; 57(4):652-8. View

17.

Nagahara Y, Enosawa S, Ikekita M, Suzuki S, Shinomiya T . Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology. 2000; 48(1):75-85. DOI: 10.1016/s0162-3109(00)00181-8. View

18.

Frasch S, Henson P, Kailey J, Richter D, Janes M, Fadok V . Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. J Biol Chem. 2000; 275(30):23065-73. DOI: 10.1074/jbc.M003116200. View

19.

Nagahara Y, Ikekita M, Shinomiya T . Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol. 2000; 165(6):3250-9. DOI: 10.4049/jimmunol.165.6.3250. View

20.

Nikolova Z, Hof A, Baumlin Y, Hof R . The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD. Transpl Immunol. 2000; 8(2):115-24. DOI: 10.1016/s0966-3274(00)00016-2. View